600812 华北制药
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入7,560,236-5.20%10,120,20110,499,94710,384,57511,492,504
减:营业总成本7,395,586-5.90%10,043,24710,311,94010,357,93011,420,314
    其中:营业成本5,272,198-3.16%6,883,6146,995,0266,702,6167,381,622
               财务费用326,812-7.23%472,747551,566576,466577,244
               资产减值损失8,351-136.99%(14,475)(65,933)13,051(24,961)
公允价值变动收益------------
投资收益33,416-2.18%46,85144,02139,11626,436
    其中:对联营企业和合营企业的投资收益32,48510.73%41,72942,42637,42821,386
营业利润223,09584.39%156,453(567,634)136,031184,148
利润总额222,97675.46%158,536(565,074)134,905186,680
减:所得税费用76,535-0.22%109,148113,70799,52382,203
净利润146,441190.66%49,388(678,782)35,382104,477
减:非控股权益43,97796.24%44,49810,45016,6557,153
股东净利润102,464266.29%4,890(689,232)18,72797,324

市场价值指针
每股收益 (元) *0.060275.00%0.003-0.4020.0110.060
每股派息 (元) *----0.010--0.0600.029
每股净资产 (元) *3.1270.64%3.0983.0893.5473.755
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容